Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Interferon in relapsing-remitting multiple sclerosis.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Focal vibration in neurorehabilitation.
Architecture of human mTOR complex 1.
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Launch of a phase 3 clinical trial in the treatment of Alzheimer’s disease with masitinib
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.

Pages